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Abstract 
 
The 3-day course on the managed introduction of new drugs was organised by the Piperska group 
together with the Agency for Health Technology Assessment and Tariff System (AOTMiT) and WHO 
Europe to share experiences and case histories among health authority and health insurance 
company personnel, academics and those from commercial organisations from across Europe on 
potential ways to optimise the managed entry of new medicines. This starts pre-launch with horizon 
scanning and budgeting, then peri-launch including critical drug evaluation, and finally post launch 
including monitoring prescribing of new medicines against agreed guidance and indicators. There 
were also discussions on issues regarding managed entry schemes and procurement strategies 
including biosimilars.  
 
Key words: Biosimilars, DTCs, horizon scanning, HTA, indicators, managed entry schemes, 
medicines.  
 
Introduction 
 
Pharmaceutical expenditure is a concern driven by factors including new high priced medicines (1-4), 
resulting in new models, starting pre-launch, through peri-launch to post launch (1, 2). These three 
pillars formed the basis of the 3-day course organised by the Piperska group (5), the Agency for 
Health Technology Assessment and Tariff System (AOTMiT) (6) and WHO Europe. 
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Course proceedings (key highlights) 
 
%HDWD0DáHFND-Libera, the Secretary of State in the Polish Ministry of Health, discussed the need for 
data on efficacy and cost effectiveness and the role of AOTMiT when assessing the value of new 
medicines. As a Government Plenipotentiary for the draft Act on public health, she emphasised that 
access to new medicines is important but underlined that there are numerous non-drug interventions 
carried out by authorities that can improve the health of the population. 
 
Hanne Bak-Pedersen discussed the principles for the appropriate use of medicines and current 
challenges with over 16,000 medicines in development (7), as well as the importance of making 
transparent, evidence informed choices when expanding benefit packages. Access to essential, 
quality and affordable medicines is central to achieving universal health coverage. Proposals include 
developing new models (4) and using HTA to support reimbursement negotiations as well as 
formulating demand-side strategies. 
 
Poland is also developing strategies to enhance the rational use of medicines, outlined by the 
president of the National Health Fund - TadeuV]-ĊGU]HMF]\N7KHLQWURGXFWLRQRIOLPLWJURXSVDQG
limits that promote cheaper generics help control expenditures, with pharmacies obligated to inform 
customers about cheaper generics. Pharmaceutical manufacturers also partly cover over-budget 
expenditure through pay-back systems. Monitoring prescribing and influencing prescribers reduces 
inappropriate medicine use and costsLQFOXGLQJPHDVXUHVWROLPLWSK\VLFLDQV¶ZULWLQJWKDW medicines 
cannot be substituted. Future measures include additional education of physicians and patients about 
medicines and potential alternatives.  
 
Rickard Malmstrom discussed the experiences in WKH6WRFNKROP5HJLRQEDVHGRQWKHµ:LVH/LVW¶
encompassing approximately 200 medicines (8). High adherence is achieved by involving 20 expert 
groups, comprehensive communication programmes and regular feedback (9). A step wise model for 
new medicines has been in operation since 2006 (10). Critical drug evaluation reports for new 
medicines are available up to six months before launch, with joint guidelines produced before launch. 
The comprehensive pre-launch campaign with dabigatran limited bleeding episodes in practice (11), 
and agreed guidance limited ipilimumab for malignant melanoma given potential costs of 
approximately 40million SEK (Euro 4.3 million).  
 
Horizon scanning is operated by 4-county collaboration in Sweden, including identification and 
filtering, prioritization, early assessment, dissemination and monitoring. The annual forecasting report 
in Stockholm is published by March each year (10). Roberta Joppi discussed the activities of 
EuroScan as well as the Italian Horizon Scanning project (12). The latter has four specific aims: (i) 
producing periodical lists of emerging medicines for which marketing authorization is expected within 
12-36 months; (ii) evaluating clinical impact and cost effectiveness/ budget impact of new medicines; 
(iii) giving well-timed information to authorities and (iv) identifying further research fields.   
 
Richard Torbett (EFPIA) stressed investment is needed for new medicines to support ageing 
populations (3,7). This provides a VROLGIUDPHZRUNIRUµvDOXH¶GLVFXVVLRQVentailing a four stage 
process including agreeing outcome metrics as well as measuring and making the results transparent. 
As a result, alLJQLQJµWUDGLWLRQDO¶DQGµ%LJ'DWD¶DSSURDFKHVWRVXSSRUWRXWFRPHVIRFXVHGpatient care.  
 
0DáJRU]DWD%DáDGLVFXVVHGNH\DVSHFWVUHJDUGLQJFULWLFDOHYDOXDWLRQRInew medicines including (i) 
systematic error; (ii) systematic disposition of trial designs to produce results consistently better or 
worse than others; (iii) tendency to deviate in one direction from a true value; (iv) threats to internal 
validity of studies. Biases include (i) selection bias, (ii) performance bias, (iii) detection bias; (iv) 
attrition bias and (v) reporting bias (13).  
 
Anna Zawada discussed critical evaluation of new medicines by AOTMiT. The current threshold for 
economic effectiveness (,&(5LV[*'3per capita FXUUHQWO\3/1¼IRUall 
medicines including orphan medicines, helped by narrow indications and risk sharing schemes. In 
2015, there were 20 submissions. Added clinical value was proved in only 6 cases. In 6 cases, the 
budget impact estimation was criticized - in 2 cases estimations were much higher than in the 
submission and in 2 cases Agency estimations were lower.  
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Key reimbursement criteria for new medicines in Slovenia include: (i) public health priority; (ii) clinical 
criteria; (iii) economic criteria including an economic analysis (ICER current 1.5 x GDP at 25 000 
¼4$/<and budget impact analysis (first three years); (iv) ethical criteria, e.g. orphan diseases and 
(v) reference sources. Discounts, rebates, price ± volume agreements/ pay-back schemes or 
performance-based agreements are taken into consideration. The latter only for the most expensive 
medicines. 
 
Reimbursement criteria for new medicines in Lithuania include: (i) therapeutic value including level of 
innovation ± 2 to 5 points (5 for a new active substance where no previous treatment) and therapeutic 
benefit - 3 to 10 points with 10 points for a new medicine with considerable value, and with 1 point 
deducted for concerns with efficacy, safety or QoL, (ii) economic value - based on pharmacoeconomic 
value (score 1.5, 3, 4.5) and price (0, 1, 2 or 3 where 3 is the lowest price in Europe based on 15 
countries) and (iii) budget impact. For positive listing, new medicines must have (i) therapeutic value 
>9; (ii) pharmacoeconomic value >4 and (iii) negative (neutral) impact on NHIF budget. If therapeutic 
value >11; pharmacoeconomic value >4, and positive impact to NHIF budget, subsequently placed on 
a waiting list. In 2014, 59 decisions of which 22 were positive, 24 negative and 13 medicines placed 
on the waiting list. The waiting list is revised every 6 month, and if budget permits medicines from the 
waiting list are included in the positive list.  
 
The Scottish Medicines Consortium (SMC) deals with uncertainty by (i) Pre-submission Guidance to 
Manufacturers stressing the need to test uncertainty; (ii) validation of assumptions and requests for 
additional analysis during NDC review; (iii) discussions regarding orphan medicines and other 
modifiers during SMC discussions. Patient access schemes (PAS) can enhance the value of new 
medicines, with these issues encompassed iQ60&¶V guidance to manufacturers (14). Angela 
Timoney also discussed formularies in Scotland including the Lothian Region to improve medicine 
use, based on their 2013 to 2016 Pharmacy Strategy (15) and their Strategic Workplan. NHS Lothian 
has a strong record of governance in medicines management including the Lothian Joint Formulary 
giving first and second line choices. Key elements to enhance formulary use include making them 
easy to follow and clinically attractive, being flexible and responsive with regular updates, and thinking 
locally whilst acting nationally 
 
Germany also formally assess the level of innovation of new medicines based on a six-point scale 
and linked to prices (16). 132 substances have been assessed (as of early March 2015). Of these, 37 
had additional benefit; 26 with partial additional benefit; 55 without additional benefit; 6 exempt and 8 
cancelled/ withdrawn. Factors influencing contracted prices include innovation levels and prices after 
deducting discounts among 15 European countries, purchasing power adjusted. Estimated savings of 
¼PLOOLRQwere generated from these negotiations between 2012 and 2014.  
 
Bjorn Wettermark discussed monitoring the utilization and outcome of new medicines and experience 
of registries (17). Key elements include relevant and valid data on exposure and outcomes, 
classification systems, quality indicators, robust and valid methods. Study designs can be descriptive, 
analytical or interventional.  
 
Key messages for developing quality indicators (QIs), building on suggestions for new medicines (18), 
include: (i) using only valid and reliable indicators to assess quality use of medicines; (ii) QIs are not a 
magic bullet but are important tools; (iii) Prescribing QIs should be developed using systematic 
methods; (iv) QIs must take implementation issues into account. Dimensions include (i) perspective; 
(ii) structure - process ± outcome; (iii) Drug, disease or patient-oriented indicators. Indicators in 
Germany to improve prescribing include monitoring drug costs among physicians, their share of 
generic scripts and share of µme-to scripts¶ especially with high potential savings. QIs include share of 
prescriptions causing adverse reactions and share of elderly patients receiving potentially inadequate 
medication, especially as 44 % of the elderly are exposed to at least one potential interaction of at 
least moderate degree and 14 % to a severe degree. There is now a 2015 framework for economic 
prescribing including enalapril, lisinopril, and ramipril as 75% of DDDs of all renin-angiotensin 
inhibitors including aliskeren.  
 
Successful multifaceted approaches in Slovenia to reduce antibiotic utilisation involved extensive 
educational programmes, QIs and prescribing restrictions (19). There are also ongoing programmes 
to reduce polypharmacy (16) involving QIs and Pharmacotherapy groups. Measures in Poland to 
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reduce antibiotic utilisation include making prescriptions valid for 7 days, specifying the antibiotic 
spectrum and ideally using sensitivity analysis. However this is not necessary if physicians are 
cognisant of the likely causes of the infection. This initiative reduced antibiotic prescribing and costs, 
e.g. 23, 941 million packages in 2013 down from 31,549 in 2011 and reimbursed costs down from 
PLN 361, 849 million in 2011 to PLN 275,121 million in 2013.  
 
The WHO recently updated its Essential Medicines List including oncology medicines (20). Key issues 
included defining clinically relevant benefits alongside the high cost of new cancer medicines (1,4,21). 
 
Finally, the goal of the Norwegian Drug procurement cooperation (LIS) is to achieve good prices for 
pharmaceuticals and reduce costs. In 2015, Orion offered a 69% discount for biosimilar infliximab 
compared with the originator tender price (REMICADE) and 72% compared with its list price (18). 
Concerns with potential side-effects are being countered by the Ministry of Health funding NOR-
SWITCH to comparing originators and biosimilars (22). Other successes included paclitaxel at 149N 
Kroner for 50mls in 2012 vs. 13, 474 for the originator in 2000. 
 
The course was well received (maximum score of 5) with speakers knowledgeable in their area and 
clarifying the content (4.8 to 4.9), the content appropriate for the audience with appropriate teaching 
methods (4.5 to 4.8), which could be applied in practice to achieve personal aims (4.6), and enhance 
SHRSOH¶VH[SHUWLVHVRPHZKDWDQGVXEVWDQWLDOO\(YHU\RQHUHFRPPHQGHGWKHFRXUVHto 
others.  
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